Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
PHVS Analyst Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PHVS Stock 12 Month Forecast
Average Price Target
$41.00
▲(55.19% Upside)
| Highest Price Target$60.00 | Average Price Target$41.00 | Lowest Price Target$30.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Morgan Stanley
$37→$41
Buy
55.19%
Upside
Reiterated
12/04/25
Oppenheimer
$44→$50
Buy
89.25%
Upside
Reiterated
12/04/25
Leerink Partners
$28→$38
Buy
43.83%
Upside
Reiterated
12/03/25
Pharvaris' Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price TargetWe are updating our model following the disclosure of Pharvaris' (PHVS, OP) positive topline data from the RAPIDe-3 study; our PT moves to $38 (from $28) and we reiterate our Outperform rating. This morning, the company reported overwhelmingly positive results from the Ph.3 RAPIDe-3 study (NCT06343779), which explored deucrictibant (PHA121), an oral small-molecule antagonist of the bradykinin B2 receptor (B2R), as an on-demand treatment for hereditary angioedema (HAE) attacks. See our first take (Pharvaris' HAEDay is the Mark). On the primary endpoint of focus, the median time to onset of symptom relief, this was 1.28 hours for deucrictibant, which is aligned with the top end of our base case (our preview here), and appears competitive with KalVista's (KALV, OP) Ekterly (sebetralstat).
H.C. Wainwright
$60
Buy
127.10%
Upside
Reiterated
12/03/25
Promising Potential of Pharvaris's Deucrictibant in HAE Treatment Drives Buy RatingValuation and Risks. We value Pharvaris using a sum-of-the-parts (SOTP) and discounted cash flow (DCF)- based methodology based on net income per asset and free cash flow to the firm (FCFF), respectively. We assign probabilities of success for deucrictibant of 90% in HAE on-demand, 90% in HAE prophylaxis, and 50% in AAE- C1INH. We employ a discount rate of 12% and a terminal multiple of 6.0x.
JonesTrading
$43→$48
Buy
81.68%
Upside
Reiterated
12/03/25
Guggenheim
$32→$39
Buy
47.62%
Upside
Reiterated
12/03/25
Bank of America Securities
$27→$30
Hold
13.55%
Upside
Reiterated
12/03/25
Cantor Fitzgerald
$33
Buy
24.91%
Upside
Reiterated
11/20/25
Citizens JMP
$55→$52
Buy
96.82%
Upside
Reiterated
08/13/25
Unknown Analyst
WedbushNot Ranked
Wedbush
$27
Buy
2.20%
Upside
Reiterated
05/14/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
$37→$41
Buy
55.19%
Upside
Reiterated
12/04/25
Oppenheimer
$44→$50
Buy
89.25%
Upside
Reiterated
12/04/25
Leerink Partners
$28→$38
Buy
43.83%
Upside
Reiterated
12/03/25
Pharvaris' Deucrictibant Shows Promising Efficacy and Safety in RAPIDe-3 Study, Analyst Sets Buy Rating with Increased Price TargetWe are updating our model following the disclosure of Pharvaris' (PHVS, OP) positive topline data from the RAPIDe-3 study; our PT moves to $38 (from $28) and we reiterate our Outperform rating. This morning, the company reported overwhelmingly positive results from the Ph.3 RAPIDe-3 study (NCT06343779), which explored deucrictibant (PHA121), an oral small-molecule antagonist of the bradykinin B2 receptor (B2R), as an on-demand treatment for hereditary angioedema (HAE) attacks. See our first take (Pharvaris' HAEDay is the Mark). On the primary endpoint of focus, the median time to onset of symptom relief, this was 1.28 hours for deucrictibant, which is aligned with the top end of our base case (our preview here), and appears competitive with KalVista's (KALV, OP) Ekterly (sebetralstat).
H.C. Wainwright
$60
Buy
127.10%
Upside
Reiterated
12/03/25
Promising Potential of Pharvaris's Deucrictibant in HAE Treatment Drives Buy RatingValuation and Risks. We value Pharvaris using a sum-of-the-parts (SOTP) and discounted cash flow (DCF)- based methodology based on net income per asset and free cash flow to the firm (FCFF), respectively. We assign probabilities of success for deucrictibant of 90% in HAE on-demand, 90% in HAE prophylaxis, and 50% in AAE- C1INH. We employ a discount rate of 12% and a terminal multiple of 6.0x.
JonesTrading
$43→$48
Buy
81.68%
Upside
Reiterated
12/03/25
Guggenheim
$32→$39
Buy
47.62%
Upside
Reiterated
12/03/25
Bank of America Securities
$27→$30
Hold
13.55%
Upside
Reiterated
12/03/25
Cantor Fitzgerald
$33
Buy
24.91%
Upside
Reiterated
11/20/25
Citizens JMP
$55→$52
Buy
96.82%
Upside
Reiterated
08/13/25
Unknown Analyst
WedbushNot Ranked
Wedbush
$27
Buy
2.20%
Upside
Reiterated
05/14/25
Best Analysts Covering Pharvaris
1 Month
xxx
Success Rate
14/22 ratings generated profit
Average Return
+1.83%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +1.83% per trade.
3 Months
xxx
Success Rate
14/22 ratings generated profit
Average Return
+3.26%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +3.26% per trade.
1 Year
Success Rate
16/22 ratings generated profit
Average Return
+37.85%
reiterated a buy rating 4 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +37.85% per trade.
2 Years
xxx
Success Rate
20/22 ratings generated profit
Average Return
+24.75%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +24.75% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PHVS Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
19
9
8
7
9
Buy
3
5
6
7
8
Hold
0
0
1
2
3
Sell
3
3
2
1
0
Strong Sell
0
0
0
0
0
total
25
17
17
17
20
Each month's total comprises the sum of three months' worth of ratings.
PHVS Financial Forecast
PHVS Stock Forecast FAQ
What is PHVS’s average 12-month price target, according to analysts?
Based on analyst ratings, Pharvaris’s 12-month average price target is 41.00.
What is PHVS’s upside potential, based on the analysts’ average price target?
Pharvaris has 55.19% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PHVS a Buy, Sell or Hold?
Pharvaris has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is Pharvaris’s price target?
The average price target for Pharvaris is 41.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $30.00. The average price target represents 55.19% Increase from the current price of $26.42.
The highest analyst price target is $60.00 ,the lowest forecast is $30.00. The average price target represents 55.19% Increase from the current price of $26.42.
What do analysts say about Pharvaris?
Pharvaris’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of PHVS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.